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Abstract
African trypanosomes exert significant morbidity and mortality in man and livestock. Only a few
drugs are available for the treatment of trypanosome infections and therefore, the development of
new anti-trypanosomal agents is required. Previously it has been shown that bloodstream-form
trypanosomes are sensitive to the iron chelator deferoxamine. In this study the effect of 13 iron
chelators on the growth of Trypanosoma brucei, T. congolense and human HL-60 cells was tested in
vitro. With the exception of 2 compounds, all chelators exhibited anti-trypanosomal activities, with
50% inhibitory concentration (IC50) values ranging between 2.1 – 220 µM. However, the iron
chelators also displayed cytotoxicity towards human HL-60 cells and therefore, only less favourable
selectivity indices compared to commercially available drugs. Interfering with iron metabolism may
be a new strategy in the treatment of trypanosome infections. More specifically, lipophilic iron-
chelating agents may serve as lead compounds for novel anti-trypanosomal drug development.
Background
Trypanosoma brucei and  T. congolense are the causative
agents of sleeping sickness in humans and nagana in cat-
tle, respectively. The protozoan parasites live extracellu-
larly in blood and tissue fluids of mammals and are
transmitted by the bite of infected tsetse flies (Glossina
spp.). Over 60 million people living in 36 sub-Saharan
countries are threatened with sleeping sickness [1] and
48000 deaths were reported in 2002 [2]. In addition, 46
million cattle are exposed to the risk of contracting nagana
and the disease costs an estimated 1340 million USD per
year [3]. Chemotherapy of African trypanosomiasis still
relies on drugs developed decades ago and some of these
display serious toxic side effects [4,5]. In addition, drug
resistance in African trypanosomes is increasing [6,7].
Thus, new strategies to treat African trypanosomes are
required.
In contrast to mammalian cells, bloodstream-form
trypanosomes require only small amounts of iron for
growth [8]. The reason for this is that bloodstream-form
trypanosomes lack cytochromes and contain only four
iron-dependent enzymes: aconitase, alternative oxidase,
ribonucleotide reductase and superoxide dismutase.
Recently, it has been shown that incubation of T. brucei
bloodstream forms with the iron chelator deferoxamine
results in growth inhibition of the parasite [9]. The com-
pound does not inhibit iron-containing enzymes directly
but acts by chelating cellular iron thus preventing its
incorporation into newly synthesised apoproteins [9].
Here we investigated the trypanocidal activity of 13 chela-
tors known to be able to complex iron ions against blood-
stream forms of T. brucei and T. congolense in vitro. For
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comparison, the general cytotoxicity of the compounds
was assayed with human myeloid leukaemia HL-60 cells.
Results
The anti-trypanosomal activities and the general cytotox-
icities of chelators were evaluated using the Alamar Blue®
assay [10,11]. For each reagent, the 50% inhibitory con-
centration (IC50) value, i.e. the concentration of a com-
pound necessary to reduce the growth rate of the cells by
50% of that of controls, was determined. With the excep-
tion of 5-sulfosalicylic acid and dimethylglyoxime, all
other compounds displayed anti-trypanosomal activities,
with IC50 values varying 100-fold (Table 1). Generally, T.
congolense  was somewhat less susceptible to the com-
pounds than T. brucei. A similar observation was recently
made for the anti-trypanosomal activities of alkaloids
[11]. The most trypanocidal chelators were deferoxamine
(Desferal®), 1,10-phenanthroline and its 4,7-diphenyl
and 2,9-dimethy-4,7diphenyl (bathocuproine, a Cu1+
chelator) derivatives, and 8-hydroxyquinoline with IC50
values in the micromolar range. Thus, the anti-trypano-
somal activities of these compounds are approaching
those of commercial drugs used to treat sleeping sickness
(suramin: IC50 = 0.4 µM) and nagana (diminazene acetu-
rate (Berenil®): IC50 = 0.5 µM) previously determined for
bloodstream forms of T. brucei 427-221a and T. congolense
STIB910 under identical experimental conditions [11].
Except for 5-sulfosalicylic acid, bathocuproine, dimethyl-
glyoxime and quercetin, all other chelators were also
active against HL-60 cells, with IC50 values ranging from
6.2 µM to 97 µM (Table 1). However, the IC50 ratios of
cytotoxic/trypanocidal activity (selectivity index) were
found to be in a modest range for all compounds (Table
1). Only deferoxamine (Desferal®) and 4,7-diphenyl-
1,10-phenanthroline gave IC50 ratios between 10 and 30
(Table 1). For comparison, commercially available drugs
used for treatment of sleeping sickness and nagana have
significant higher selectivity indices (suramin: IC50 ratio =
1944; diminazene aceturate: IC50 = 692 [11]).
Discussion
Compounds with a high affinity for iron are common in
nature, especially in micro-organisms. Numerous iron
chelators, so-called siderophores, have been isolated from
bacteria and fungi [12]. Deferoxamine is such an iron che-
lator produced by the bacterium Streptomyces pilosus. It has
been developed into the drug Desferal® which is used for
the treatment of acute iron poisoning and chronic iron-
overload. In addition, deferoxamine has been shown to
exhibit trypanocidal activity against bloodstream forms of
T. brucei [9]. Here we demonstrated that deferoxamine is
not only active to T. brucei but also to T. congolense blood-
stream forms.
The isolation of siderophores in sufficient quantities for
clinical applications is difficult and expensive. Therefore,
other iron chelators which can be synthetically produced
have been investigated in this study. 2,3-Dihydroxyben-
zoic acid and ethylenediamine-di-o-hydroxyphenylacetic
acid are such synthetic iron chelators which have been
used in patients with β-thalassaemia major [13] and to
induce iron-deficiency in micro-organisms [14], respec-
tively. However, both compounds only exhibited a weak
Table 1: IC50 values of iron chelators for bloodstream forms of T. brucei 427-221a and T. congolense STIB910, and for human myeloid 
leukaemia HL-60 cells, and IC50 ratios of cytotoxic to trypanocidal activities of the chelators.
Compound IC50 (µM) IC50 ratio
T. brucei T. congolense HL-60 cells T. brucei/HL-60 T. congolense/HL-60
Deferoxamine 3.3 3.4 97.0 29.4 28.5
2,3-Dihydroxybenzoic acid 220 n.d.† n.d n.d. n.d
Ethylenediamine-di-o-hydroxyphenylacetic acid 120 n.d. 325 2.7 n.d.
5-Sulfosalicylic acid >1000 * >1000 * >1000 * 1 1
Tropolone 12.5 18.7 6.2 0.5 0.3
5-Methyl-tropolone 15.7 20.0 31.1 2.0 1.6
2,2'-Bipyridine 46.2 67.0 28.3 0.6 0.4
2,4,6-Tris(2-pyridyl)-1,3,5-triazine 28.6 75.0 90.1 3.2 1.2
1,10-Phenanthroline 3.3 5.3 8.5 2.6 1.6
4,7-Diphenyl-1,10-phenanthroline 2.0 4.5 48.3 24.2 10.7
Bathocuproine‡ 3.0 >10 * >10 * >3.3 1
8-Hydroxyquinoline 2.1 206 7.7 3.7 0.03
Dimethylglyoxime >100 * >100 * >100 * 1 1
Quercetin 16.3 62.6 >100 * >6.1 >1.6
*The highest concentration tested.
†n.d., not determined.
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trypanocidal effect. 5-Sulfosalicylic acid is another com-
pound which complexes iron ions over a wide pH range
but showed no toxic effect for trypanosomes and mam-
malian cells. The low anti-trypanosomal activities of these
compounds may be due to their water solubility. Simi-
larly, a reduced trypanocidal activity was recently
observed for water-soluble derivatives of the DNA topoi-
somerase inhibitor camptothecin [15].
In contrast to water-soluble chelators, hydrophobic com-
pounds displayed much better anti-trypanosomal activi-
ties. Tropolone is a lipid solubilizing agent for cationic
metals and has been shown to release iron from cells [16].
It exhibited moderate trypanocidal activities but was also
very toxic for mammalian cells. Its 5-methyl derivative
showed similar anti-trypanosomal actions but with
reduced cytotoxicity. 8-Hydroxyquinoline is a well-
known lipophilic iron chelator [17] and is used as a disin-
fectant. It was very effective in killing bloodstream forms
of T. brucei, however, no prediction can be made regarding
its mechanism of action because of the lack of selectivity
for metal ions. Quercetin is a flavonoid with metal chelat-
ing properties. It was only moderately toxic to trypano-
somes. This may be due to its antioxidant properties [18]
counteracting its trypanocidal effect as a chelator depriv-
ing the cell of iron. 2,2'-Bipyridine is a membrane-per-
meant, intracellular Fe2+ chelator and has been shown to
inhibit DNA virus replication by blocking the incorpora-
tion of iron into viral apoprotein ribonucleotide reductase
[19]. However, 2,2'-bipyridine displayed only some
trypanocidal activity like the related compound 2,4,6-
tris(2-pyridyl)-1,3,5-triazine. On the other hand, 1,10-
phenanthroline, a 2,2'-bipyridine derivative with
increased lipophilicity and reduced free rotatability, sub-
stantially inhibited the growth rate of both trypanosomes
and mammalian cells. The 4,7-diphenyl derivative of
1,10-phenanthroline showed a similar trypanocidal activ-
ity as its parent compound but was less cytotoxic. How-
ever, the anti-trypanosomal action of phenanthrolines
seems not to be by depleting the parasites of iron. Against
this is the observation that Fe2+ and Cu1+ complexes of
4,7-diphenyl-1,10-phenanthroline display similar
trypanocidal activities (data not shown). In addition,
bathocuproine (2,9-dimethyl-4,7-diphenyl-1,10-phenan-
throline), another lipophilic phenanthroline derivative
that selectively complexes Cu1+ with no affinity for Fe2+,
was also similarly toxic to trypanosomes. It seems that the
lipophilicity of the compounds is the crucial factor. It is
possible that phenanthrolines incorporate into mem-
branes or intercalate into DNA and induce structural
changes. In support of this, it has been shown that Fe2+
complexes involving 1,10-phenanthroline and 4,7-diphe-
nyl-1,10-phenanthroline bind to DNA [20].
Conclusion
Iron deprivation may be a new strategy for the treatment
of African trypanosomiasis. Although the compounds
investigated in this study are not suitable for clinical use,
our results suggest that lipophilic iron-chelating agents
have a potential as novel anti-trypanosomal drugs. This
finding may also be exploited in the future by utilizing the
wealth of information currently being generated in the
development of cell-permeable iron chelators as cancer
chemotherapeutic agents [21-23]. In addition, future
efforts should also aim at improving the selectivity of iron
chelators. Moreover, iron chelators may be of interest for




Alamar Blue® was from BioSource (Camarillo, CA, USA);
EMEM with L-glutamine and without phenol red and foe-
tal bovine serum were from Life Technologies (Eggen-
stein, Germany); RPMI 1640 without L-glutamine and
without phenol red was from Bioproducts (Heidelberg,
Germany); goat serum was from Boehringer Mannheim
(Mannheim, Germany). Desferal was obtained from
Ciba-Geigy (Wehr, Germany). All other chelators were
from Sigma (Deisenhofen, Germany) or Fluka (Buchs,
Switzerland). The Fe2+ complexes of 1,10-phenanthroline
and 4,7-diphenyl-1,10-phenanthroline, and 5-methyl-
tropolone were kindly provided by Professor Michael
Wink (Institute of Pharmacy and Molecular Biotechnol-
ogy, Ruprecht-Karls-University, Heidelberg, Germany).
Cells
Bloodstream forms of T. brucei TC221 was derived from
the stock 427 [24] and was obtained from Prof. Peter
Overath (Max-Planck Institute für Biologie, Tübingen,
Germany). The animal origin of the T. brucei stock 427
cannot be definitely clarified anymore. Bloodstream
forms of T. congolense STIB910 was cloned from T. congo-
lense STIB249 which was isolated from a lion in Tansania
in 1971 [25]. T. congolense STIB910 was kindly provided
by Prof. Reto Brun (Swiss Tropical Institute, Switzerland).
Human myeloid leukaemia HL-60 cells were obtained
from the Deutsche Sammlung von Mikroorganismen und
Zellkulturen GmbH (Braunschweig, Germany).
Cell culture
Bloodstream forms of T. brucei and  T. congolense were
grown in Baltz medium [26] (EMEM plus 25 mM HEPES,
2.5 mM glucose, 1 mM Na-pyruvate, 0.05 mM hypoxan-
thine, 0.001 mM thymidine, 0.04 mM adenosine, 0.025
mM bathocuproindisulfonic acid, pH 7.5, 10 ml/l nones-
sential amino acids (100×)) supplemented with 16.7%
heat-inactivated foetal bovine serum and goat serum,
respectively, and 0.2 mM 2-mercaptoethanol. HumanKinetoplastid Biology and Disease 2006, 5:3 http://www.kinetoplastids.com/content/5/1/3
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myeloid leukaemia HL-60 cells were propagated in RPMI
1640 medium supplemented with 2 mM L-glutamine and
10% heat-inactivated foetal bovine serum. All cultures
were maintained in a humidified atmosphere containing
5% CO2 at 37°C (T. brucei and HL-60 cells) or at 34°C (T.
congolense).
Toxicity assays
Cells were seeded into 96-well tissue culture plates in 200
µl medium containing various concentrations of chelators
dissolved in H2O (deferoxamine, 2,3-dihydroxybenzoic
acid, ethylenediamine-di-o-hydroxyphenylacetic acid, 5-
sulfosalicylic acid, tropolone, 5-methyl-tropolone, 2,2'-
bipyridine, 1,10-phenanthroline), 99% ethanol (2,4,6-
tris(2pyridyl)-1,3,5-triazine, 4,7-diphenyl-1,10-phenan-
throline, 8-hydroxyquinoline, dimethylglyoxime, querce-
tin), or 100% DMSO (bathocuproine). The controls
contained the respective solvent alone. In all experiments,
the final solvent concentration was 1% which had no
effect on cell growth. To ensure that the cells were in log-
arithmic growth phase during the entire experiment, they
were seeded at an initial density of 1 × 104 T. brucei/ml, 4
× 105 T. congolense/ml, and 1 × 105 HL-60/ml, respectively.
After 24 h (trypanosomes) or 43 h (HL-60) incubation, 20
µl of the colorimetric viability indicator Alamar Blue® was
added to each well. The cells were incubated for a further
24 h (trypanosomes) or 5 h (HL-60) so that the total incu-
bation time was 48 h. Then, the plates were read on a
Dynatech MR5000 ELISA reader (Denkendorf, Germany),
using a test wavelength of 550 nm and a reference wave
length of 630 nm. Each test was set up in duplicate and
repeated three times. The IC50 value was determined by
linear interpolation according to the method described in
[27].
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